Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder

Trials

Volumn 11, Issue , 2010, Pages

  Miskowiak, Kamilla W ^a   Vinberg, Maj ^a   Harmer, Catherine J ^b   Ehrenreich, Hannelore ^c   Knudsen, Gitte M ^a   Macoveanu, Julian ^d   Hansen, Allan R ^a   Paulson, Olaf B ^a,d   Siebner, Hartwig R ^d   Kessing, Lars V ^a  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIDEPRESSANT AGENT; ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EMOTION; FLU LIKE SYNDROME; HAMILTON SCALE; HEADACHE; HUMAN; INJECTION SITE RASH; MAJOR DEPRESSION; NERVE CELL PLASTICITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; REY AUDITORY VERBAL LEARNING TEST; SEIZURE; SYMPTOM; TREATMENT OUTCOME; VERBAL MEMORY; AFFECT; ATTENTION; CLINICAL PROTOCOL; COGNITION; DENMARK; EXECUTIVE FUNCTION; MEMORY; METHODOLOGY; NEUROPSYCHOLOGICAL TEST; PLACEBO EFFECT; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; TIME;

AFFECT; ANTIDEPRESSIVE AGENTS; ATTENTION; BIPOLAR DISORDER; CLINICAL PROTOCOLS; COGNITION; DENMARK; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; EXECUTIVE FUNCTION; HUMANS; MEMORY; NEURONAL PLASTICITY; NEUROPSYCHOLOGICAL TESTS; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957725156     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-97     Document Type: Article

References (64)

1. Hamilton M. A Rating Scale for Depression. Journal of Neurology Neurosurgery and Psychiatry 1960, 23:56-62.
2. Rey A. Psychological examination of traumatic encephalopathy. Archieves de Psychologic 1941, 28:286-340. Ref Type: Generic.
3. Rey A. L'examen clinique en psychologie. Paris 1964,
4. Clark L, Goodwin GM. State- and trait-related deficits in sustained attention in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2004, 254:61-68. 10.1007/s00406-004-0460-y, 15146334.
5. Dittmann S, Hennig-Fast K, Gerber S, Seemuller F, Riedel M, Severus W, et al. Cognitive functioning in euthymic bipolar I and bipolar II patients. Bipolar Disorders 2008, 10:877-887. 10.1111/j.1399-5618.2008.00640.x, 19594503.
6. Kessing LV. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med 1998, 28:1027-1038. 10.1017/S0033291798006862, 9794010.
7. Martinez-Aran A, Vieta E, Colom F, Reinares M, Benabarre A, Gasto C, et al. Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. Psychother Psychosom 2000, 69:2-18. 10.1159/000012361, 10601830.
8. Martinez-Aran A, Vieta E, Colom F, Torrent C, Sanchez-Moreno J, Reinares M, et al. Cognitive impairment in euthymic bioplar patients: implications for clinical and functional outcome. Bipolar Disorders 2004, 6:224-232. 10.1111/j.1399-5618.2004.00111.x, 15117401.
9. Zubieta JK, Huguelet P, O'Neil RL, Giordani BJ. Cognitive function in euthymic Bipolar I Disorder. Psychiatry Research 2001, 102:9-20. 10.1016/S0165-1781(01)00242-6, 11368835.
10. Chamberlain SR, Sahakian BJ. Cognition in mania and depression: psychological models and clinical implications. Curr Psychiatry Rep 2004, 6:451-458. 10.1007/s11920-004-0010-3, 15538994.
11. Wingo AP, Harvey PD, Baldessarini RJ. Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disorders 2009, 11:113-125. 10.1111/j.1399-5618.2009.00665.x, 19267694.
12. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151. 10.1038/nrn1846, 16429123.
13. Frey BN, Andreazza AC, Nery FG, Martins MR, Quevedo J, Soares JC, et al. The role of hippocampus in the pathophysiology of bipolar disorder. Behav Pharmacol 2007, 18:419-430. 10.1097/FBP.0b013e3282df3cde, 17762510.
14. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000, 5:578-593. 10.1038/sj.mp.4000811, 11126389.
15. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809. 10.1126/science.1083328, 12907793.
16. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
17. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nature Reviews Neuroscience 2005, 6:484-494. 10.1038/nrn1687, 15928718.
18. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000, 97:10526-10531. 10.1073/pnas.97.19.10526, 27058, 10984541.
19. Sattler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bahr M, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004, 11(Suppl 2):S181-S192. 10.1038/sj.cdd.4401504, 15459752.
20. Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Molecular Psychiatry 2007, 12:206-220. 10.1038/sj.mp.4001907, 17033631.
21. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007, 130:2577-2588. 10.1093/brain/awm203, 17728357.
22. Viviani B, Bartesaghi S, Corsini E, Villa P, Ghezzi P, Garau A, et al. Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. J Neurochem 2005, 93:412-421. 10.1111/j.1471-4159.2005.03033.x, 15816864.
23. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35:1732-1737. 10.1161/01.STR.0000132196.49028.a4, 15178821.
24. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003, 198:971-975. 10.1084/jem.20021067, 2194205, 12975460.
25. Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovitch AG, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 2005, 19:1701-1703.
26. Fu CHY, Mourao-Miranda J, Costafrecla SG, Khanna A, Marquand AF, Williams SCR, et al. Pattern classification of sad facial processing: Toward the development of neurobiological markers in depression. Biological Psychiatry 2008, 63:656-662. 10.1016/j.biopsych.2007.08.020, 17949689.
27. Marquand AF, Mourao-Miranda J, Brammer MJ, Cleare AJ, Fu CHY. Neuroanatomy of verbal working memory as a diagnostic biomarker for depression. Neuroreport 2008, 19:1507-1511. 10.1097/WNR.0b013e328310425e, 18797307.
28. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. American Journal of Psychiatry 2004, 161:1256-1263. 10.1176/appi.ajp.161.7.1256, 15229059.
29. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biological Psychiatry 2006, 59:816-820. 10.1016/j.biopsych.2005.10.015, 16460693.
30. Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, et al. Effect of Acute Antidepressant Administration on Negative Affective Bias in Depressed Patients. American Journal of Psychiatry 2009, 166:1178-1184. 10.1176/appi.ajp.2009.09020149, 19755572.
31. Bhagwagar Z, Cowen PJ, Goodwin GM, Harmer CJ. Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression. American Journal of Psychiatry 2004, 161:166-168. 10.1176/appi.ajp.161.1.166, 14702268.
32. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. Biological Psychiatry 2001, 50:651-658. 10.1016/S0006-3223(01)01263-X, 11704071.
33. Miskowiak K, O'Sullivan U, Harmer CJ. Erythropoietin reduces neural and cognitive processing of fear in human models of antidepressant drug action. Biol Psychiatry 2007, 62:1244-1250. 10.1016/j.biopsych.2007.01.011, 17553466.
34. Miskowiak K, O'Sullivan U, Harmer CJ. Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci 2007, 27:2788-2792. 10.1523/JNEUROSCI.5013-06.2007, 17360900.
35. Miskowiak K, Inkster B, O'Sullivan U, Selvaraj S, Goodwin GM, Harmer CJ. Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res 2008, 184:313-321. 10.1007/s00221-007-1102-1, 17828390.
36. Miskowiak K, Inkster B, Selvaraj S, Wise R, Goodwin GM, Harmer CJ. Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. Neuropsychopharmacology 2008, 33:611-618. 10.1038/sj.npp.1301439, 17473836.
37. Girgenti MJ, Hunsberger J, Duman CH, Sathyanesan M, Terwilliger R, Newton SS. Erythropoietin Induction by Electroconvulsive Seizure, Gene Regulation, and Antidepressant-Like Behavioral Effects. Biological Psychiatry 2009, 66:267-274. 10.1016/j.biopsych.2008.12.005, 19185286.
38. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003, 23:6690-6694.
39. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, Cowen PJ, et al. Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology (Berl) 2009, 207:133-142. 10.1007/s00213-009-1641-1, 19705104.
40. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435. 10.1192/bjp.133.5.429, 728692.
41. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
42. Fava M, Iosifescu DV, Pedrelli P, Baer L. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009, 78:91-97. 10.1159/000201934, 19218827.
43. EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990, 16:199-208. 10.1016/0168-8510(90)90421-9, 10109801.
44. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990, 47:589-593.
45. Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK, et al. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 2009, 4:e5894. 10.1371/journal.pone.0005894, 2690401, 19521513.
46. McIntyre RS, Rasgon NL, Kemp DE, Nguyen HT, Law CW, Taylor VH, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009, 9:51-59. 10.1007/s11892-009-0010-0, 19192425.
47. Smith DJ, Muir WJ, Blackwood DHR. Neurocognitive impairment in euthymic young adults with bipolar spectrum disorder and recurrent major depressive disorder. Bipolar Disorders 2006, 8:40-46. 10.1111/j.1399-5618.2006.00275.x, 16411979.
48. Ekman P, Friesen WV. Pictures of facial affect 1976, Palo Alto: Consulting Psychologists Press.
49. Beccari M. Seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention. Int J Artif Organs 1994, 17:5-13.
50. Locatelli F, Del VL, Pozzoni P. Pure red-cell aplasia "epidemic"--mystery completely revealed?. Perit Dial Int 2007, 27(Suppl 2):S303-S307.
51. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008, 48:1754-1762. 10.1111/j.1537-2995.2008.01749.x, 2730535, 18482185.
52. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369:381-388. 10.1016/S0140-6736(07)60194-9, 17276778.
53. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e647-e656. 10.1161/STROKEAHA.109.564872, 19834012.
54. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996, 19:179-200. 10.1016/S0193-953X(05)70283-5, 8827185.
55. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003, 53:649-659. 10.1016/S0006-3223(03)00231-2, 12706951.
56. Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry 2007, 190:287-292. 10.1192/bjp.bp.106.028555, 17401033.
57. Ferrario E, Ferrari L, Bidoli P, De CD, Del VM, De DS, et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004, 30:563-575. 10.1016/j.ctrv.2004.04.005, 15325036.
58. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003, 100:6741-6746. 10.1073/pnas.1031753100, 164517, 12746497.
59. Erbayraktar S, de LN, de LA, Knisely JP, Erbayraktar Z, Yilmaz O, et al. Carbamylated erythropoietin reduces radiosurgically-induced brain injury. Mol Med 2006, 12:74-80. 10.2119/2006-00042.Erbayraktar, 1578768, 16953562.
60. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242. 10.1126/science.1098313, 15247477.
61. King VR, Averill SA, Hewazy D, Priestley JV, Torup L, Michael-Titus AT. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 2007, 26:90-100. 10.1111/j.1460-9568.2007.05635.x, 17614942.
62. Mahmood A, Lu D, Qu C, Goussev A, Zhang ZG, Lu C, et al. Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 2007, 107:392-397. 10.3171/JNS-07/08/0392, 17695395.
63. Wang Y, Zhang ZG, Rhodes K, Renzi M, Zhang RL, Kapke A, et al. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007, 151:1377-1384. 10.1038/sj.bjp.0707285, 2189829, 17603558.
64. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005, 387:5-10. 10.1016/j.neulet.2005.07.008, 16054296.